Zynex, Inc. (NASDAQ:ZYXI) Short Interest Down 13.2% in March

Zynex, Inc. (NASDAQ:ZYXI - Get Free Report) was the recipient of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 3,830,000 shares, a decline of 13.2% from the February 28th total of 4,410,000 shares. Currently, 20.4% of the shares of the stock are sold short. Based on an average trading volume of 201,300 shares, the short-interest ratio is presently 19.0 days.

Zynex Stock Performance

Shares of Zynex stock traded down $0.09 on Friday, reaching $2.16. The stock had a trading volume of 332,273 shares, compared to its average volume of 149,523. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. The business's 50-day moving average price is $5.90 and its two-hundred day moving average price is $7.38. The stock has a market cap of $68.93 million, a P/E ratio of 14.40 and a beta of 0.81. Zynex has a fifty-two week low of $2.11 and a fifty-two week high of $12.84.

Zynex (NASDAQ:ZYXI - Get Free Report) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.11). The business had revenue of $45.98 million for the quarter, compared to analyst estimates of $53.65 million. Zynex had a return on equity of 13.05% and a net margin of 2.49%. During the same period in the prior year, the firm posted $0.04 EPS. On average, sell-side analysts forecast that Zynex will post 0.2 EPS for the current year.

Remove Ads

Insider Buying and Selling

In other Zynex news, CFO Daniel J. Moorhead sold 10,000 shares of the business's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $7.68, for a total transaction of $76,800.00. Following the sale, the chief financial officer now owns 19,738 shares in the company, valued at approximately $151,587.84. The trade was a 33.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 52.13% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ZYXI. R Squared Ltd acquired a new position in Zynex in the fourth quarter worth about $26,000. Tower Research Capital LLC TRC grew its stake in shares of Zynex by 138.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,398 shares of the company's stock valued at $27,000 after purchasing an additional 1,975 shares during the period. Investment Partners Asset Management Inc. raised its holdings in shares of Zynex by 10.4% in the 4th quarter. Investment Partners Asset Management Inc. now owns 12,942 shares of the company's stock worth $104,000 after buying an additional 1,220 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Zynex during the 4th quarter worth approximately $117,000. Finally, Dimensional Fund Advisors LP boosted its stake in Zynex by 9.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 19,333 shares of the company's stock valued at $155,000 after buying an additional 1,660 shares in the last quarter. 29.68% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ZYXI shares. LADENBURG THALM/SH SH cut Zynex from a "buy" rating to a "neutral" rating in a research report on Wednesday, March 12th. HC Wainwright decreased their price objective on Zynex from $17.00 to $15.00 and set a "buy" rating for the company in a research report on Wednesday, March 12th. Finally, Royal Bank of Canada cut Zynex from an "outperform" rating to a "sector perform" rating and lowered their target price for the company from $11.00 to $5.50 in a research note on Wednesday, March 12th.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.